ReviewFrontiers in pharmacology2026
RNA-based approaches in the diagnosis and treatment of obesity.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a global, complex, and multifactorial disease, and a major risk factor for diabetes, cardiovascular disease, fatty liver disease, and cancer. Despite its high prevalence, effective diagnostic and therapeutic strategies remain limited. Conventional anthropometric measurements, such as body mass index (BMI) and waist circumference, offer limited accuracy in assessing the impact of excess adiposity and related comorbidities on individual patients. Current anti-obesity pharmacotherapies also show inconsistent efficacy, are often associated with systemic side effects, and poor adherence to necessary lifestyle modifications, which limit their long-term success. Emerging evidence underscores the critical role of non-coding RNAs, including microRNAs, long non-coding RNAs, circular RNAs, and tRNA-derived small RNAs in key metabolic processes such as adipogenesis, insulin signalling, and appetite control. Notably, the profiles of many circulating miRNAs have been reported to differ between patients with obesity compared to healthy lean individuals, suggesting their potential as minimally invasive diagnostic biomarkers. In this mini-review, we discuss the clinical promise of RNA-based approaches for disease risk assessment and as therapeutic targets in obesity. In addition, we discuss key challenges, including biomarker validation and effective RNA delivery systems to the target organs. Multi-omics approaches may help overcome many of these limitations and enable the development of targeted and personalized RNA-based anti-obesity therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.